A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Inclusion Criteria:
Exclusion Criteria:
medinfo@amgen.com866-572-6436
Los Angeles, California 90095, United States
Whittier, California 90602, United States
Grand Junction, Colorado 81505, United States
New Britain, Connecticut 06053, United States
Norwich, Connecticut 06360, United States
Jacksonville, Florida 32256, United States
Rockford, Illinois 61108, United States
Indianapolis, Indiana 46202, United States
Wichita, Kansas 67214, United States
Minneapolis, Minnesota 55407, United States
East Syracuse, New York 13057, United States
Eugene, Oregon 97401, United States
Nashville, Tennessee 37203, United States
Morgantown, West Virginia 26506, United States
Ciudad Autonoma de Buenos Aires, Buenos Aires C1431FWO, Argentina
Yvoir, 5530, Belgium
Belo Horizonte, Minas Gerais 30130-090, Brazil
Porto Alegre, Rio Grande do Sul 90610-000, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
Saint-Herblain, 44800, France
Shatin, New Territories, Hong Kong
Kurume-shi, Fukuoka 830-0011, Japan
Akashi-shi, Hyōgo 673-8558, Japan
Hirakata-shi, Osaka 573-1191, Japan
Sakai-shi, Osaka 590-0197, Japan
Hidaka-shi, Saitama 350-1298, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Matosinhos Municipality, 4464-513, Portugal
Cheongju Chungbuk, 28644, South Korea
Goyang-si Gyeonggi-do, 10408, South Korea